New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease ...Middle East

InPedILD Phase III trial showed encouraging results for both primary endpoints. Full data were published in the European Respiratory Journal and presented at the European Respiratory Society International Congress in Barcelona, Spain If approved, nintedanib would become the first approved...

Hence then, the article about new data from boehringer ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease was published today ( Monday 05/09/2022 - 03:28 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease )

Also on site :

• Baltimore officer, suspect shot in 'active shooter incident'
• 10 Essential Episodes of ‘The Orville’
• Fans Say Andre Agassi Was 'Made For This' 90s Instagram Trend: 'You Win'